Sellas Life Sciences Group Inc. (RXK3)
XMUN 
Summary
RXK3 Chart
SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Event
SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sellas Life Sciences Group Inc. (RXK3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sellas Life Sciences Group Inc. ever had a stock split?
Sellas Life Sciences Group Inc. Profile
| Biotechnology Industry | Healthcare Sector | Angelos Stergiou CEO | XMUN Exchange | US81642T2096 ISIN |
| US Country | 13 Employees | - Last Dividend | 14 Nov 2016 Last Split | 29 Dec 2017 IPO Date |
Overview
SELLAS Life Sciences Group, Inc. is a distinguished late-stage clinical biopharmaceutical company with a focused aim on the advancement of innovative cancer immunotherapies across a multitude of cancer indications within the United States. The company is engaged in pioneering the development of novel therapeutic agents that have the potential to significantly improve the treatment landscape for patients battling various forms of cancer. Through its strategic collaborations with industry leaders like Merck & Co., Inc. and GenFleet Therapeutics (Shanghai), Inc., SELLAS is at the forefront of exploring synergistic therapeutic strategies that could enhance the efficacy of its leading product candidate. The company's headquarters are strategically located in New York, New York, signifying its centrality in the biopharmaceutical innovation hub.
Products and Services
- Galinpepimut-S (GPS)
GPS represents a groundbreaking cancer immunotherapeutic agent engineered to target the Wilms tumor 1 (WT1) antigen, a critical molecular target in oncology given its universal overexpression in a wide range of malignant tumors. SELLAS's pioneering approach with GPS encompasses:
- A pivotal Phase 3 clinical trial aimed at acute myeloid leukemia (AML), a formidable challenge in cancer treatment due to its rapid progression and high relapse rates.
- Initiation of Phase 1/2 clinical trials exploring the effectiveness of GPS in treating ovarian cancer, aiming to establish a new therapeutic avenue for managing this often difficult-to-treat malignancy.
- Collaborative Research and Development
In a strategic collaboration with Merck & Co., Inc., SELLAS is engaged in the exploration of GPS in combination with pembrolizumab, a PD1 blocker, within a Phase 1/2 clinical trial. This trial is ambitiously enrolling patients across up to five cancer indications, covering both hematologic malignancies and solid tumors, aiming to harness the combined therapeutic potential of these agents.
- Additionally, the partnership with GenFleet Therapeutics focuses on the development and commercialization of GFH009, a highly selective CDK9 inhibitor. This molecule, currently under a Phase 1 clinical trial, represents another frontier of SELLAS’s exploration into next-generation cancer therapeutics, targeting mechanisms underlying cancer cell proliferation and survival.
